Search Results - "tyrosine kinase"

Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis by Timothy J. Turner, Pricilla Brun, Ross C. Gruber, Dimitry Ofengeim

Connect to this object online.

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor by Heather Zhang, Ying C. Ou, Dan Su, Fan Wang, Lai Wang, Srikumar Sahasranaman, Zhiyu Tang

Connect to this object online.

Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria by Veselina Goranova-Marinova, Daniela Grekova-Kafalova, Kalina Andreevska, Vania Georgieva, Yana Gvozdeva, Margarita Kassarova, Zhanet Grudeva-Popova, Evelina Gavazova, Valentina Petkova

Connect to this object online.

Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer by Alyson Yoder, Landon J. Inge, Chen-Chun Chen, Vijay R. Marati, Trung Kien Nguyen, Karel Zuiderveld, Jim Martin, Sarah Gladden, Mohammad Saleh Miri, Raghavan Venugopal, Bryan Lopez, Jim Ranger-Moore, Christoph Guetter

Connect to this object online.

Adverse event profiles of epidermal growth factor receptor‐tyrosine kinase inhibitors in cancer patients: A systematic review and meta‐analysis by Xiaonan Yin, Zhou Zhao, Yuan Yin, Chaoyong Shen, Xin Chen, Zhaolun Cai, Jian Wang, Zhixin Chen, Yiqiong Yin, Bo Zhang

Connect to this object online.

Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis? by Wulyo Rajabto, Noviana Joenputri

Connect to this object online.

Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells by Maria Krchniakova, Maria Krchniakova, Silvia Paukovcekova, Petr Chlapek, Petr Chlapek, Jakub Neradil, Jakub Neradil, Jan Skoda, Jan Skoda, Renata Veselska, Renata Veselska

Connect to this object online.

Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors by Alessandro Allegra, Giuseppe Mirabile, Santino Caserta, Fabio Stagno, Sabina Russo, Giovanni Pioggia, Sebastiano Gangemi

Connect to this object online.

Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia by Carmen Rădulescu, Anca Bacârea, Adina Huțanu, Rozalia Gabor, Minodora Dobreanu

Connect to this object online.

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation by Po-Yen Chen, Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chien-Ning Hsu, Chung-Yu Chen, Chung-Yu Chen, Chung-Yu Chen, Chung-Yu Chen

Connect to this object online.

Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors by Delong Liu, Karen Seiter, Nasir Ahmed, Samir Patel, Xuan Huang

Connect to this object online.

Role of Soluble FMS-Like Tyrosine Kinase (SFLT-1) /Placental Growth Factor (Plgf) Ratio as Prognostic Marker for Cases of Preeclampsia by Gasser M Elbishry, Ihab F Serag Eldin, Ahmed A ElShahawy, Gihan E Hawwary, Ahmed M Riad

Connect to this object online.

Thyroid Cancer The Road From Genes to Successful Treatment

Subjects: “…tyrosine kinase inhibitors…”
DOAB: download the publication
DOAB: description of the publication

Peripheral T-cell Lymphomas

Subjects: “…epigenetics, genomics, targeted therapy, precision medicine, transcriptomics, tyrosine kinase inhibitors…”
DOAB: download the publication
DOAB: description of the publication

Study of the interaction of the GSB-106 BDNF neurotrophin dipeptide mimetic with the TrkB tyrosine kinase receptor using surface plasmon resonance technology by A. V. Tarasiuk, Y. V. Mezentsev, O. V. Gnedenko, P. Yu. Povarnina, A. S. Ivanov

Connect to this object online.

Correction to: Fischer et al., Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

Connect to this object online.

Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary by Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Zsolt Abonyi-Toth, Judit Demeter

Connect to this object online.

Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies by Adel S. El-Azab, Abdullah Al-Dhfyan, Alaa A.-M, Laila A. Abou-Zeid, Hamad M. Alkahtani, Abdulrahman M. Al-Obaid, Manal A. Al-Gendy

Connect to this object online.

An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia by Mahmoud Fathy Hassan, Nancy Mohamed Ali Rund, Ahmed Husseiny Salama

Connect to this object online.

Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma by Yue Chen, Yue Chen, Yutao Wang, Yutao Wang, Jin Lei, Bowen Chen, Bowen Chen, Xinfeng Zhang, Xinfeng Zhang, Liangzheng Chang, Zhangli Hu, Yun Wang, Yinying Lu, Yinying Lu, Yinying Lu

Connect to this object online.